|
Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients with HIV Associated Large Cell and Immunoblastic Lymphomas Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients with HIV Associated Large Cell and Immunoblastic Lymphomas conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients with HIV Associated Large Cell and Immunoblastic Lymphomas Clinical research trials and Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients with HIV Associated Large Cell and Immunoblastic Lymphomas health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients with HIV Associated Large Cell and Immunoblastic Lymphomas. Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients with HIV Associated Large Cell and Immunoblastic Lymphomas Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients with HIV Associated Large Cell and Immunoblastic Lymphomas clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients with HIV Associated Large Cell and Immunoblastic Lymphomas condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients with HIV Associated Large Cell and Immunoblastic Lymphomas  Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients with HIV Associated Large Cell and Immunoblastic Lymphomas
Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients with HIV Associated Large Cell and Immunoblastic Lymphomas
For Condition: Lymphoma, Non-Hodgkin,HIV Infections
Status: Completed
Sponsor(s): Lederle Laboratories ,
Synopsis: To determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride ( Novantrone ) and etoposide in the treatment of patients with HIV associated lymphomas.
Details:
Eligibility:
Study Type: Interventional, Treatment, Dose Comparison, Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have the following: - Positive HIV antibody, positive HIV culture or antigen capture, or prior diagnosis of AIDS by the CDC criteria. - Diagnosis by pathological examination of large cell or immunoblastic lymphoma within measurable or evaluable disease. - Pneumocystis carinii pneumonia (PCP) prophylaxis during the course of the study. - Signed written informed consent. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia (PCP) diagnosed within 3 weeks. - Stage IE Central Nervous System lymphomas. Patients with the following are excluded: - More than one previous treatment for lymphoma. - Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia (PCP) diagnosed within 3 weeks. - Conditions that preclude obtaining an informed consent. - Not accessible for scheduled treatment visits or follow-up. - Stage IE Central Nervous System (CNS) lymphomas. Prior Medication: Excluded within 2 weeks of study entry: - Zidovudine. - Excluded: - Doxorubicin dosing = or > 300 mg/m2. Prior Treatment: Excluded: - Received more than one previous treatment regimen for lymphoma. Required: - Prophylactic treatment for Pneumocystis carinii pneumonia (PCP) prophylaxis.
Total Enrollment:
Location and Contact Information:
Saint Luke's - Roosevelt Hosp Ctr
New York City, New York, 10019
United States
UMDNJ - New Jersy Med School
Newark, New Jersey, 071032714
United States
New York Univ Med Ctr
New York City, New York, 10016
United States
Additional Information:
Study ID Numbers: 055A; 3-100
Study Start Date:
Record last reviewed: March 1992
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002003
Other Lymphoma, Non-Hodgkin Studies:
1. Gene Therapy in HIV-Positive Patients with Non-Hodgkin's Lymphoma
2. Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors
3. A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines
4. Meaning-Centered Psychotherapy in Advanced Cancer
5. Proleukin in Combination with Rituxan in Patients with Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments
Related Studies:
Other Lymphoma, Non-Hodgkin Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients with HIV Associated Large Cell and Immunoblastic Lymphomas
|
|
|
|
|
|
|
|
